Interní Med. 2006; 8(3): 119-122

Some new therapeutics for postmenopausal osteoporosis

prof. MUDr. Vladimír Palička CSc, doc. MUDr. Pavel Živný CSc, MUDr. Ladislava Pavlíková

Ústav klinické biochemie a diagnostiky FN a LF UK Hradec Králové

The Recommended Guidelines for diagnostics and therapy of primary postmenopausal osteoporosis are still valid and basic steps – supplementation of calcium and vitamin D are basic stones of successful therapy. Hormonal replacement therapy is not considered as a primary and first choice therapy; it is considered as a therapy of menopausal syndrome with positive effect on bone metabolism. Antiresorptive drugs on the Czech market (bisphosphonates, calcitonine, selective estrogen receptor modulators) were enhanced by two osteoanabolic drugs. Stroncium ranelate is the first drug with dual effect on bone metabolism: osteoanabolic and antiresorptive. It could be a promising drug for patients with the attenuation of bone anabolic steps. Teriparatide, very strong osteoanabolic drug, is the recombinant human 1-34 PTH. Teriparatide stimulates bone forming on trabecular as well as on cortical bone. The necessity of daily parenteral application and high price make this drug the special one for patients without any success in other types of therapy. Compliance of any type of therapy remains the main target for future.

Keywords: Key words: osteoporosis, therapy, stroncium ranelate, teriparatide, compliance.

Published: June 1, 2006  Show citation